About: The Risk of Diabetes on Clinical Outcomes in Patients with Coronavirus Disease 2019: A Retrospective Cohort Study

Facets (new session)
Description
Metadata
Settings
- owl:sameAs
- Inference Rule:

About: The Risk of Diabetes on Clinical Outcomes in Patients with Coronavirus Disease 2019: A Retrospective Cohort Study Goto Sponge NotDistinct Permalink

An Entity of Type : schema:ScholarlyArticle, within Data Space : wasabi.inria.fr associated with source document(s)

Attributes	Values
type	Academic Article research paper schema:ScholarlyArticle
isDefinedBy	Covid-on-the-Web dataset
title	The Risk of Diabetes on Clinical Outcomes in Patients with Coronavirus Disease 2019: A Retrospective Cohort Study
Creator	Lee, Kwan Shin, Kyeong-Cheol Choi, Eun Yoon, Ji Hong, Kyung Chung, Jin Chung, Seung Jin, Hyun Moon, Jun Ahn, June Ha, Eunyeong Hur, Jian Jang, Jong Lee, Hyoung Lee, Yin Won, Kyu
source	Medline; PMC
abstract	BACKGROUND: To determine the role of diabetes mellitus (DM) in the coronavirus disease 2019 (COVID-19), we explored the clinical characteristics of patients with DM and compared risk factors such as age, glycemic control, and medications to those without DM. METHODS: This was a retrospective cohort study of 117 confirmed patients with COVID-19 which conducted at a tertiary hospital in Daegu, South Korea. The primary outcome was defined as the severe and critical outcome (SCO), of which the composite outcomes of acute respiratory distress syndrome, septic shock, intensive care unit care, and 28-day mortality. We analyzed what clinical features and glycemic control-related factors affect the prognosis of COVID-19 in the DM group. RESULTS: After exclusion, 110 participants were finally included. DM patients (n=29) was older, and showed higher blood pressure compared to non-DM patients. DM group showed higher levels of inflammation-related biomarkers and severity score, and highly progressed to SCO. After adjustment with other risk factors, DM increased the risk of SCO (odds ratio [OR], 10.771; P<0.001). Among the DM patients, SCO was more prevalent in elderly patients of ≥70 years old and age was an independent risk factor for SCO in patients with DM (OR, 1.175; P=0.014), while glycemic control was not. The use of medication did not affect the SCO, but the renin-angiotensin system inhibitors showed protective effects against acute cardiac injury (OR, 0.048; P=0.045). CONCLUSION: The COVID-19 patients with DM had higher severity and resulted in SCO. Intensive and aggressive monitoring of COVID-19 clinical outcomes in DM group, especially in elderly patients is warranted.
has issue date	2020-05-21(xsd:dateTime)
bibo:doi	10.4093/dmj.2020.0105
bibo:pmid	32602272
has license	cc-by-nc
sha1sum (hex)	ab0f88b962d7237f5d0dba3ffa20ef8c0118cde1
schema:url	https://doi.org/10.4093/dmj.2020.0105
resource representing a document's title	The Risk of Diabetes on Clinical Outcomes in Patients with Coronavirus Disease 2019: A Retrospective Cohort Study
has PubMed Central identifier	PMC7332325
has PubMed identifier	32602272
schema:publication	Diabetes Metab J
resource representing a document's body	covid:ab0f88b962d7237f5d0dba3ffa20ef8c0118cde1#body_text
is schema:about of	named entity 'USE OF MEDICATION' named entity 'NON-' named entity 'PROGNOSIS' named entity 'RISK OF' named entity 'DID' named entity 'BIOMARKERS' named entity '110' named entity 'TERTIARY' named entity 'METHODS' named entity 'RENIN-ANGIOTENSIN SYSTEM' named entity 'ELDERLY PATIENTS' named entity 'CONCLUSION' named entity 'SEVERITY' named entity 'DPP4' named entity 'influenza' named entity 'lactate dehydrogenase' named entity 'Acute respiratory distress syndrome' named entity 'HbA1c' named entity 'septic shock' named entity 'COVID-19' named entity 'COVID' named entity 'Daegu' named entity 'glycemic control' named entity 'tertiary hospital' named entity 'glycemic control' named entity 'risk factors' named entity 'septic shock' named entity 'elderly patients' named entity 'South Korea' named entity 'intensive care unit' named entity 'risk factor' named entity 'HbA1c' named entity 'diabetic patients' named entity 'pulse oximetry' named entity 'COVID' named entity 'electronic medical records' named entity 'MERS-CoV' named entity 'neutrophil' named entity 'intensive care unit' named entity 'SARS' named entity 'ARDS' named entity 'informed consent' named entity 'hypertension' named entity 'cellular receptor' named entity 'DPP4' named entity 'Armonk' named entity 'reverse transcriptase' named entity 'hydroxychloroquine' named entity 'hyperglycemia' named entity 'SARS-CoV' named entity 'COVID' named entity 'glycemic control' named entity 'ICU' named entity 'fasting plasma glucose' named entity 'P<0.05' named entity 'COVID-19' named entity '28 days' named entity 'insulin' named entity 'bilateral pneumonia' named entity 'virus' named entity 'prognosis' named entity 'complement' named entity 'diabetes' named entity 'China' named entity 'high-risk' named entity 'physical examination'

Faceted Search & Find service v1.13.91 as of Mar 24 2020

Alternative Linked Data Documents: Sponger | ODE Content Formats:

RDF

ODATA

Microdata

About

OpenLink Virtuoso version 07.20.3229 as of Jul 10 2020, on Linux (x86_64-pc-linux-gnu), Single-Server Edition (94 GB total memory)
Data on this page belongs to its respective rights holders.
Virtuoso Faceted Browser Copyright © 2009-2025 OpenLink Software